



NEWS RELEASE

# Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

4/8/2024

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)-- **Ventus Therapeutics, Inc.**, a clinical-stage biopharmaceutical company utilizing its deep protein science expertise and proprietary computational chemistry platform, ReSOLVE™, to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, being held April 16-17 in Toronto. Dr. Bigal will be presenting on April 16th at 11:30 AM ET.

## About Ventus Therapeutics

Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. Using its proprietary drug discovery platform, ReSOLVE™, the company screened its first target in 2020, selected three development candidates in 2022, and advanced its two wholly-owned product candidates into the clinic in 2023: VENT-03, a potent, selective, oral cGAS inhibitor in Phase 1, and VENT-02, a highly potent, brain-penetrant, oral NLRP3 inhibitor in Phase 1. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These programs exemplify Ventus' robust discovery capabilities and focus on differentiated programs for multi-indication immunology and neurology targets. For more information, please visit [www.ventustx.com](http://www.ventustx.com) and engage with Ventus on [LinkedIn](#).

Forward-Looking Statements



This press release contains forward-looking statements about future expectations, plans, and prospects, including, but not limited to, statements related to the anticipated benefits of Ventus' business strategy, pipeline programs, drug discovery platform, and financial position. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to the risks and uncertainties inherent in Ventus' business, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE™ platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers, manufacturers, and CROs; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

## Media

Alexis Feinberg

ICR Westwicke

203-939-2225

**[Alexis.Feinberg@westwicke.com](mailto:Alexis.Feinberg@westwicke.com)**

Source: Ventus Therapeutics, Inc.